Clinical Trials Logo

Infantile Hemangioma clinical trials

View clinical trials related to Infantile Hemangioma.

Filter by:

NCT ID: NCT05479123 Recruiting - Clinical trials for Infantile Hemangioma

Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas

Start date: June 23, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the baseline sleep pattern disruption for patients starting oral propranolol at the standard BID dosing regimen compared to the control (timolol) group and to determine if there is a significant improvement in the sleep patterns in infants taking oral propranolol on the TID dosing regimen versus the control (timolol) group

NCT ID: NCT04684667 Not yet recruiting - Clinical trials for Infantile Hemangioma

''Efficacy of Propranolol in the Treatment of Infantile Hemangioma"

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

''Evaluation of the Efficacy of Propranolol in the Treatment of Infantile Hemangioma"

NCT ID: NCT04288700 Recruiting - Clinical trials for Infantile Hemangioma

Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma

Start date: October 1, 2019
Phase: Phase 4
Study type: Interventional

Is to compare and evaluate the efficacy of oral captopril with oral propranolol, intralesional propranolol injection, and topical Timolol in the treatment of infantile hemangioma and their effect on vascular endothelial growth factor and CD 133.

NCT ID: NCT04105517 Completed - Clinical trials for Infantile Hemangioma

Hemangiol, Post Marketing Surveillance Study

postHemangiol
Start date: July 1, 2019
Phase:
Study type: Observational

Infantile hemangioma is a benign tumor belonging to the group of vascular tumors in the ISSVA classification (International Society for the Study of Vascular Anomalies). The diagnosis is clinical and radiological. The hemangioma appears during the first weeks of life (70% classically within 2 weeks after birth) but can, when it develops in the subcutaneous tissue, appear until the age of 2 to 3 months . Its evolution is characteristic and is divided into 3 phases with a proliferative phase characterized by a rapid increase in the size of the tumor (up to 6 to 12 months), a phase of stabilization (from 12 to 36 months) with a stopping of the growth of the hemangioma and a regression of its size and a phase of involution with the disappearance of the lesion which may give way to residual fibroadipose tissue, cutaneous telangiectases, scars … The usual complications of haemangiomas occur during the proliferative phase. It is necrosis, ulcerations that can be complicated by bleeding or infection and eventually indelible scarring. Other complications related to the site of development of hemangiomas (amblyopia, astigmatism, upper respiratory obstruction, nasal obstruction, sphincter disorders, eating disorders), hemangiomas destroying structures noble (breast hypodévelopment, alopecia). The aesthetic prognosis can be seriously compromised for facial locations. Historically, when drug therapy was required, patient management was based on systemic corticosteroids (at doses of 3 to 5 mg / kg / day) in first-line therapy and vincristine as a second-line failure of corticosteroid therapy or when life-threatening is at stake. In 2014, the high French health authority (HAS) gave Marketing Authorization for Hemangiol 3.75 mg / ml oral solution for the management of infantile proliferative hemangioma requiring first-line systemic treatment, evaluating the actual benefit as important. The selected indication concerns children from 5 weeks to 5 months with: - Hemangiomas leading to a vital or functional risk, - Hemangiomas ulcerated painful and / or not responding to simple care, - Hemangiomas with a risk of permanent scarring or disfigurement. The 2014 HAS Transparency Commission wishes in its report "to have follow-up data of prescriptions allowing to describe on a representative sample of patients, the characteristics of the treated patients, the indication, the doses and the durations of treatment of this specialty ". The objective of our study is to describe the use of Hemangiol in current practice in our hospital from 2014 to 2018.

NCT ID: NCT03842631 Recruiting - Clinical trials for Infantile Hemangioma

Optimizing Timolol Maleate Treatment of Infantile Hemangioma by Doppler Ultrasound Examination

Start date: February 16, 2019
Phase:
Study type: Observational

The purpose of this study is to assess the safety and efficacy of Timolol Maleate treatment for different depth of infantile hemangioma based on B-ultrasonography. Based on the depth of hemangioma, patients will be proactively allocated to two groups. And then, all patients in both groups will receive topical timolol treatment in the same protocol and dosage.

NCT ID: NCT03237637 Recruiting - Clinical trials for Infantile Hemangioma

Comparative Study to Evaluate the Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangiomas

Start date: March 24, 2017
Phase: Phase 3
Study type: Interventional

Through this study, the investigators shall compare the effectiveness of atenolol with propranolol in the treatment of IH. In addition, the investigators shall try to elucidate the mechanism of action of beta blockers by assessing their action on triggers such as hypoxia. The study design will be a parallel group comparative study wherein patients of IH will be randomized into two groups. One group will receive propranolol and the other atenolol for a maximum period of 9 months. The patients will then be followed up regularly for regression of the IH based on Physician global assessment, hemangioma activity score(HAS), serial photography and lesional ultrasonography. Any side effects encountered during the treatment period will also be noted. Also serial measurements of hypoxia inducible factor 1 alpha(HIF-1α) will be made to ascertain the mechanism of action of the drugs.

NCT ID: NCT03173352 Recruiting - Clinical trials for Infantile Hemangioma

A Prospective Study on the Incidence and Related Risk Factors of Infantile Hemangioma in China

IH
Start date: December 2015
Phase: N/A
Study type: Observational

Infant hemangioma(IH) is the most common benign vascular tumor of infancy with the estimated incidence varies 1% to 12%.However, in China, the incidence of infant hemangioma and related epidemiological data remains unclear. So, the investigators designed the study for the following purposes: 1, to aware the incidence of infantile hemangioma and understand the related risk factorsin China; 2, to understand the clinical characteristics of infantile hemangioma and the risk factors for complications; 3, to investigate the level of knowledge, treatment options in infant hemangioma in Chinese doctors; 3, to improve the awareness of infantile hemangioma in parents and provide more advice for pregnancy counseling and eugenics.

NCT ID: NCT02913612 Completed - Clinical trials for Infantile Hemangioma

Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)

TIM01
Start date: May 5, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of Timolol 0.25% and 0.5% doses.

NCT ID: NCT02505971 Completed - Clinical trials for Infantile Hemangioma

Nadolol Versus Propranolol in Children With Infantile Hemangiomas

Start date: September 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of oral propranolol versus nadolol in patients with Infantile Hemangiomas (IH) in a randomized, controlled, double-blinded study.

NCT ID: NCT01673971 Completed - Clinical trials for Infantile Hemangioma

Optical Tomographic Imaging of Infantile Hemangiomas

Start date: May 2012
Phase:
Study type: Observational

The investigators hypothesize that there are differences between infantile hemangiomas (IH) during the proliferating and involuting phases and in response to medical treatment that can be detected by optical tomography of these hemangiomas.